Core Viewpoint - A class action lawsuit has been filed against Organon & Co. for alleged violations of federal securities laws, claiming that the company made materially false and misleading statements regarding its business and operations during the class period from October 31, 2024, to April 30, 2025 [1][2][3]. Group 1: Lawsuit Details - The lawsuit seeks to recover damages for investors who purchased Organon securities during the specified class period [2]. - Allegations include that Organon provided overly positive statements while concealing material adverse facts, particularly regarding capital allocation and a significant reduction in quarterly dividends [3]. - The complaint highlights that following the revelation of these issues, Organon's common stock price experienced a dramatic decline [3]. Group 2: Next Steps for Investors - Investors who suffered losses in Organon have until July 22, 2025, to request to be appointed as lead plaintiff in the case [4]. - A copy of the complaint can be reviewed on the law firm's website [4]. Group 3: Legal Representation - The law firm representing the investors operates on a contingency fee basis, meaning they will only collect fees if the case is successful [5]. - Bronstein, Gewirtz & Grossman, LLC is noted for recovering hundreds of millions of dollars for investors in similar cases [6].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Organon & Co. due to misleading statements regarding its capital allocation strategy, particularly concerning dividends and debt reduction, which led to significant financial losses for investors [3][5]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi is encouraging investors who suffered losses exceeding $75,000 in Organon between October 31, 2024, and April 30, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against Organon, with a deadline of July 22, 2025, for investors to seek the role of lead plaintiff [3]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [4]. Group 2: Financial Misrepresentation - Defendants provided misleading information about Organon's commitment to regular quarterly dividends, claiming it was a "1 capital allocation priority" while concealing the prioritization of debt reduction following the acquisition of Dermavant [5]. - The misleading statements resulted in a 70% decrease in the regular quarterly dividend, causing shareholders to purchase securities at artificially inflated prices [5]. Group 3: Market Reaction - Following the revelations about Organon's financial practices, the company's stock price dropped from $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025, marking a decline of over 27% in just one day [6].

Core Viewpoint - A class action has been filed against Organon & Co. for allegedly misleading investors regarding its debt reduction strategy and the prioritization of capital allocation through dividends [1][2]. Allegations - The complaint claims that during the class period, Organon misrepresented its capital allocation strategy, emphasizing dividends as a "1 capital allocation priority" while concealing the importance of its debt reduction strategy post-acquisition of Dermavant [2][3]. - It is alleged that this misrepresentation led to a significant reduction in the regular quarterly dividend by 70% [3]. Impact of Disclosure - The truth about the company's financial strategy was revealed on May 1, 2025, when Organon announced a drastic cut in its dividend payout from $0.28 to $0.02, aimed at recapturing capital [4]. - Following this announcement, Organon's stock price plummeted from $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025, marking a decline of over 27% [4].

Core Viewpoint - The Organon class action lawsuit alleges that the company and its executives made misleading statements regarding capital allocation and dividend payouts, leading to significant financial losses for investors [1][4][5]. Group 1: Lawsuit Details - The lawsuit, titled Hauser v. Organon & Co., seeks to represent purchasers of Organon securities and claims violations of the Securities Exchange Act of 1934 [1]. - The allegations include the concealment of material information about Organon's capital allocation priorities and a drastic reduction of over 70% in the quarterly dividend payout [4]. - Following the announcement of the reduced dividend from $0.28 to $0.02 on May 1, 2025, Organon's stock price fell by more than 27% [5]. Group 2: Company Background - Organon develops health solutions through prescription therapies and medical devices [3]. - The company had previously reported optimistic dividend payouts, which were later contradicted by a newly implemented debt reduction strategy following the acquisition of Dermavant Sciences Ltd [4]. Group 3: Legal Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Organon securities during the class period to seek appointment as lead plaintiff in the lawsuit [6]. - The lead plaintiff represents the interests of all class members and can select a law firm to litigate the case [6]. Group 4: Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [7]. - The firm has been ranked 1 in securing monetary relief for investors in securities class action cases for four out of the last five years [7].

Core Viewpoint - A class action lawsuit has been filed against Organon & Co. for allegedly misleading investors regarding its capital allocation strategy, particularly concerning its debt reduction efforts and dividend payouts [1][2][3]. Group 1: Allegations and Misleading Information - The complaint claims that during the class period, Organon prioritized its capital allocation strategy through regular quarterly dividends, presenting it as the "1 capital allocation priority" [2]. - It is alleged that while making these positive statements, Organon concealed the high priority of its debt reduction strategy following the acquisition of Dermavant, which led to a 70% decrease in the regular quarterly dividend [3]. Group 2: Impact of the Announcement - The truth about the company's financial strategy was revealed on May 1, 2025, when Organon announced a significant reduction in its dividend payout from $0.28 to $0.02 to recapture capital [4]. - Following this announcement, Organon's stock price fell from $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025, marking a decline of over 27% [4]. Group 3: Class Action Participation - Shareholders may be eligible to participate in the class action against Organon & Co., with options to serve as lead plaintiff or remain an absent class member [5]. - The representation in the class action is on a contingency fee basis, meaning shareholders will not incur fees or expenses [6].

Core Viewpoint - The Organon class action lawsuit alleges that the company and its executives made misleading statements regarding capital allocation and dividend payouts, leading to significant financial losses for investors [1][4][5]. Company Overview - Organon & Co. develops health solutions through prescription therapies and medical devices [3]. Allegations of the Lawsuit - The lawsuit claims that Organon concealed material information about its capital allocation priorities, particularly regarding the future of its quarterly dividend payout [4]. - It is alleged that Organon's reports on dividend payouts being a "number one priority" were misleading, as they were countered by a newly implemented debt reduction strategy, resulting in a more than 70% decrease in the quarterly dividend [4]. - Following the acquisition of Dermavant Sciences Ltd., Organon prioritized debt reduction, which was not disclosed to investors [4]. Financial Impact - On May 1, 2025, Organon reported its first quarter 2025 financial results, announcing a drastic reduction in its dividend payout from $0.28 to $0.02, which led to a more than 27% drop in the stock price [5]. Legal Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Organon securities during the class period to seek appointment as lead plaintiff in the lawsuit [6]. - The lead plaintiff represents the interests of all class members and can select a law firm for litigation [6]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [7]. - The firm has been ranked 1 in securing monetary relief for investors in securities class action cases for four out of the last five years [7].

NEW YORK, May 23, 2025 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Organon & Co. (“Organon” or the “Company”) (NYSE: OGN) between October 31, 2024, to April 30, 2025, both dates inclusive. You are hereby notified that the class action lawsuit Joseph Hauser v. Organon & Co., et al. (Case No. 2:25-cv-05322) has been commenced in the United States District Court for the District of New Jersey ...

Company Overview - Organon & Co. is a global healthcare company primarily focused on improving women's health [2] Investigation Details - Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Organon, specifically regarding false or misleading statements made by the company and its executives [1] - The investigation is aimed at determining whether Organon failed to disclose material information to investors [1] Recent Developments - On May 1, 2025, Organon announced a significant dividend cut of approximately 90%, which led to a stock price decline of more than 28% [3]

Group 1 - Organon & Co. is initiated at Strong Buy with a price target of $26.4, highlighting its diversified portfolio in Rx therapies, particularly in women's health and biosimilars [1] - The investment thesis is supported by a forecasted operational inflection, indicating potential growth and performance improvement [1] - Moretus Research emphasizes a structured approach to equity research, focusing on companies with durable business models and mispriced cash flow potential [1] Group 2 - The research methodology combines rigorous fundamental analysis with a judgment-driven process, aiming to filter out noise and overly complex forecasting [1] - Valuation is based on sector-relevant multiples tailored to each company's business model, emphasizing comparability and simplicity [1] - Moretus Research targets underappreciated companies undergoing structural changes or temporary dislocations, which can lead to asymmetric returns [1]

Core Insights - Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Organon & Co., focusing on whether the company and its executives made false or misleading statements or failed to disclose material information to investors [1][2] Company Overview - Organon is a global healthcare company primarily focused on improving the health of women [2] Recent Developments - On May 1, 2025, Organon announced a dividend cut of approximately 90%, leading to a stock price decline of more than 28% [3]